Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
Wainwright reiterated a Buy rating and a $145 price target on the stock, citing its strong growth prospects despite commercial challenges. The research firm has reiterated its confidence in the company's Korlym medication, whose sales are projected to grow by 19% to 26% year over year, affirming the underlying strong demand. Volume has increased by 40% over the past two quarters, and the company is poised to meet its guidance of $800-$850 million. Likewise, Corcept is a Buy owing to a strong balance sheet that supports the launch of two products next year. The company is on the cusp of launching relacorilant for Cushing's syndrome, with sales expected to reach $4.3 billion by 2034. On November 17, Wolfe Research began coverage of Corcept Therapeutics (NASDAQ: CORT) with a Peer Perform rating and said it expects the stock to trade in the $70- $75 range until the company's patent litigation and antitrust cases are settled. Analyst Kalpit Patel pointed to these legal issues as near
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Assessing Corcept Therapeutics (CORT) Valuation as Relacorilant Nears Key PDUFA Decision and Analyst Optimism Builds [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.MarketBeat
- Corcept Therapeutics (NASDAQ:CORT) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
CORT
Earnings
- 11/4/25 - Miss
CORT
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- CORT's page on the SEC website